The advisors will support research initiatives at the cannabinoid company
Dave Wood, Nutraceutical Advisor, Open Book Extracts
Open Book Extracts has announced the appointment of four strategic advisors to support research initiatives and boost its post-development commercialisation efforts.
Dave Wood, who most recently served as the CEO of Captek, will serve as nutraceutical advisor. Wood has had more than 30 years of management experience with an emphasis on pharmaceutical-grade manufacturing, research and development, and licensing, with background in the nutritional supplement sector.
Two cosmeceutical advisors are joining the company. Dr Jeffrey Dover, FRCPC, is co-director of SkinCare Physicians of Chestnut Hill, a dermatology, cosmetics and laser facility. He also serves as associate professor of Clinical Dermatology at Yale University School of Medicine, and associate professor of Dermatology at Brown Medical School. Dr Michael Singer, PhD, a serial biotech executive and CSO at Cartesian Therapeutics, also joins in this role.
Lastly, Dr Robert Silver is joining as veterinary advisor. Silver, DVM, MS, is a licensed integrative veterinarian, and an expert on veterinary health and medical cannabis. He is the author of Medical Marijuana and Your Pet and has recently authored four chapters in two Springer-Nature textbooks on Veterinary Cannabis. He holds adjunct faculty positions at Lincoln Memorial University’s College of Veterinary Medicine, and the Chi University of Traditional Chinese Veterinary Medicine and is president-elect of the American College of Veterinary Botanical Medicine.
“Each appointee joining OBX from sectors outside the cannabis category is a testament to the broad appeal of the industry and the unique opportunity to make an impact through OBX,” said Dave Neundorfer co-founder and CEO of Open Book Extracts.
“Bringing diverse skill sets and successful careers in pharmaceutical-grade manufacturing, consumer healthcare, gene therapies, veterinary medicine, cosmeceutical development, intellectual property and patent strategy, the advisors are already actively engaged in advancing OBX’s vision of delivering innovative, research-backed products to lead the way for cannabinoid-enabled health and wellness,” added Neundorfer.
While much of the company’s product development work is client-guided, OBX has recently begun its own research-backed product development initiatives, targeting nutraceutical, skincare, and veterinary markets. The company hopes to commercialise its findings through licensing deals and/or joint venture partnerships.
“I am delighted to join OBX as an advisor because they sit at the intersection of what matters most today – high-quality ingredient production, expert formulation services, and best-class-in finished products, development and innovation,” said Wood. “OBX is a prominent company in the cannabinoid industry and I look forward to supporting their role in accelerating the path to market success for clients around the world."